NAPERVILLE, Ill., Jan. 11, 2018 — Pharmazz, Inc. is pleased to announce that Indian Patent No. 290038 on a pharmaceutical composition comprising IRL-1620 (PMZ-1620) was granted on November 28, 2017. PMZ-1620, a selective endothelin-B receptor agonist, is presently undergoing clinical studies in patients suffering from mild to moderate Alzheimer's disease. In addition, a phase II study, using PMZ-1620, is being conducted in patients with cerebral ischemic stroke.
The company also announces the initiation of a study to evaluate PMZ-1620 in dogs with degenerative myelopathy. Degenerative myelopathy is a spinal cord disease of dogs, progressing from weakness of the hind-limbs to eventual paralysis. In many ways, degenerative myelopathy has pathological, genetic and clinical features similar to human amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Currently, there are no effective treatment options to arrest or reverse degenerative myelopathy or ALS. The Institute for Healthcare Innovation, College of Veterinary Medicine, and Chicago College of Pharmacy at Midwestern University are collaborating on a new study to evaluate PMZ-1620 in dogs with degenerative myelopathy. The peptide, PMZ-1620, has been the subject of Dr. Gulati's research at Chicago College of Pharmacy and known to have neurogenic properties, a mechanism which may have applications for degenerative myelopathy. Pharmazz, Inc. has exclusive rights to PMZ-1620 from Midwestern University and plans to initiate studies in patients with amyotrophic lateral sclerosis if the results of this study in dogs with degenerative myelopathy are positive.
About Pharmazz, Inc.
Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.
View original content:http://www.prnewswire.com/news-releases/issuance-of-patent-and-initiation-of-a-study-to-evaluate-pmz-1620-in-dogs-with-degenerative-myelopathy-a-disease-similar-to-human-amyotrophic-lateral-sclerosis-als-300581706.html
SOURCE Pharmazz, Inc.
Powered by WPeMatico